StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-18 | $2.93 | $2.85 | -2.73% | 0.2M |
| 05-19 | $2.85 | $2.80 | -1.75% | 0.1M |
| 05-20 | $2.85 | $2.93 | +2.81% | 0.1M |
| 05-21 | $2.90 | $2.92 | +0.69% | 0.1M |
| 05-22 | $2.94 | $2.92 | -0.68% | 0.1M |
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Annual 2025 2025-12-31 | Annual 2024 2024-12-31 | Q3 2024 2024-09-30 | Q2 2024 2024-06-30 |
|---|---|---|---|---|
Revenue | $8.00K | $8.00K | $8.00K | $8.00K |
Operating Income | $-33.21M | $-31.70M | $-21.95M | $-15.01M |
Net Income | $-32.15M | $-29.87M | $-20.89M | $-6.58M |
EPS (Diluted) | $-0.86 | $-0.95 | $-0.69 | $-0.51 |
Total Assets | $19.03M | $34.72M | $40.27M | $45.18M |
Total Liabilities | $7.48M | $8.44M | $7.18M | $7.51M |
Cash & Equivalents | $5.33M | $8.56M | $6.10M | $7.86M |
Free Cash Flow OCF − CapEx | $-26.37M | $-21.61M | $-17.21M | $-11.44M |
Shares Outstanding | 38.14M | 34.73M | 34.54M | 34.51M |
GNLX is in the extended universe. We surface dollar-volume + price-change percentiles for every US-listed name, but the full 6-factor DNA breakdown (momentum, news, sentiment, flow, relative strength) is only computed on the curated 1137-name primary list.
DNA analysis is not available for this ticker.
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.